Autorisation d’accès précoce refusée à la spécialité TEPEZZA (téprotumumab) dans l'indication « traitement des patients adultes atteints d’ophtalmopathie basedowienne modérée à sévère ».
See also
HAS opinions and decisions
26/02/2025
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
jsRJ46g51nGe01dx
